In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Metagenomi Inc (NASDAQ: MGX) closed at $1.61 in the last session, up 6.27% from day before closing price of $1.51. In other words, the price has increased by $6.27 from its previous closing price. On the day, 0.66 million shares were traded. MGX stock price reached its highest trading level at $1.695 during the session, while it also had its lowest trading level at $1.51.
Ratios:
We take a closer look at MGX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.85 and its Current Ratio is at 5.85. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on May 07, 2024, initiated with a Buy rating and assigned the stock a target price of $10.
On May 02, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $16 to $6.
On March 05, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $25.Wells Fargo initiated its Overweight rating on March 05, 2024, with a $25 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 06 ’25 when Wein Matthew sold 199 shares for $1.75 per share. The transaction valued at 348 led to the insider holds 16,693 shares of the business.
Noonberg Sarah B. sold 5,239 shares of MGX for $9,168 on Jun 06 ’25. The Chief Medical Officer now owns 109,135 shares after completing the transaction at $1.75 per share. On Jun 06 ’25, another insider, Wapnick Pamela, who serves as the Chief Financial Officer of the company, sold 1,576 shares for $1.75 each. As a result, the insider received 2,758 and left with 72,108 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGX now has a Market Capitalization of 60184216 and an Enterprise Value of -126208384. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.33 while its Price-to-Book (P/B) ratio in mrq is 0.28. Its current Enterprise Value per Revenue stands at -2.788 whereas that against EBITDA is 1.535.
Stock Price History:
The Beta on a monthly basis for MGX is -0.46, which has changed by -0.6129808 over the last 52 weeks, in comparison to a change of 0.1185931 over the same period for the S&P500. Over the past 52 weeks, MGX has reached a high of $5.50, while it has fallen to a 52-week low of $1.23. The 50-Day Moving Average of the stock is 0.70%, while the 200-Day Moving Average is calculated to be -24.48%.
Shares Statistics:
According to the various share statistics, MGX traded on average about 447.78K shares per day over the past 3-months and 828390 shares per day over the past 10 days. A total of 37.38M shares are outstanding, with a floating share count of 21.80M. Insiders hold about 41.67% of the company’s shares, while institutions hold 24.90% stake in the company. Shares short for MGX as of 1749772800 were 2095797 with a Short Ratio of 4.68, compared to 1747267200 on 2404470. Therefore, it implies a Short% of Shares Outstanding of 2095797 and a Short% of Float of 7.71.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
